SYRS vs TMO vs BIO vs CRL vs MEDP

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -33. 2% for Syros Pharmaceuticals, Inc. (SYRS). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 2x trailing P/E (25. 0x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 2x versus Medpace Holdings, Inc. at 28. 1x. On forward P/E, Charles River Laboratories International, Inc. is actually cheaper at 16. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 79x versus Thermo Fisher Scientific Inc. 's 9. 05x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +159. 4%, compared to -100. 0% for Syros Pharmaceuticals, Inc. (SYRS). Over 10 years, the gap is even starker: MEDP returned +1443% versus SYRS's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 92β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 65% more volatile than BIO relative to the S&P 500. On balance sheet safety, Bio-Rad Laboratories, Inc. (BIO) carries a lower debt/equity ratio of 21% versus 4% for Syros Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus -33. 2% for Syros Pharmaceuticals, Inc. (SYRS). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -1656. 3% for Syros Pharmaceuticals, Inc. — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus -1298. 2% for SYRS. At the gross margin level — before operating expenses — SYRS leads at 77. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 79x versus Thermo Fisher Scientific Inc. 's 9. 05x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Charles River Laboratories International, Inc. (CRL) trades at 16. 4x forward P/E versus 25. 2x for Medpace Holdings, Inc. — 8. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 0% to $654. 67.

In this comparison, TMO (0.

4% yield) pays a dividend. SYRS, BIO, CRL, MEDP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Both have compounded well over 10 years (MEDP: +1443%, SYRS: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SYRS is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.